基于胰高血糖素的糖尿病治疗药物研究进展

Research progress in the diabetic drags based on glucagon

基于胰高血糖素的糖尿病治疗药物中,内源性胰高血糖素能快速升高血糖,作为严重低血糖的急救药物应用于临床;胰高血糖素受体拮抗剂的研发起源于糖尿病患者胰高血糖素的过度分泌,拮抗胰高血糖素的作用能降低患者血糖;而胰高血糖素受体激动剂的研发则基于胰高血糖素升糖作用外的降脂及促进能量消耗作用,其与肠促胰素的双重受体激动剂能使肥胖的糖尿病患者进一步获益.虽然这些药物大多数尚处于临床前期的研究中,但在糖尿病治疗上,它们有望成为有效的降糖药物,将给糖尿病患者带来曙光.

Among these diabetic drugs based on glucagon,endogenous glucagon can rapidly increase blood glucose and is used as a first aid for severe hypoglycemia in clinic;the development of glucagon receptor antagonists is due to the hyperglucagon secretion in diabetic patients,anti-glucagon can lower blood glucose in diabetic patients;moreover,in addition to hyperglycemic effect,glucagon can also reduce blood lipid and promote energy consumption,which provides a theoretical basis for the research and development of glucagon receptor agonists,its dual receptor agonists with incretin can further benefit obese diabetic patients.Although most of these drugs are still in preclinical studies,they are expected to be effective drugs controlling blood glucose in the treatment of diabetes mellitus and bring hopes to patients with diabetes mellitus.